Study of Pharmacogenetic Testing to Improve Care in Emergency Departments for Adults 40 and Older

What this Trial Is About

Researchers are evaluating the use of preemptive pharmacogenetic PGx testing in emergency departments ED to see if it can help reduce return visits to the ED and hospitalizations. This study is a randomized, controlled, pragmatic clinical trial conducted at several University of Florida Health EDs. It aims to test both the practical implementation of PGx testing and its real-world effectiveness in supporting patient care. Participants are randomly assigned to one of two groups one group receives immediate panel-based pharmacogenetic genotyping, with results entered into their electronic health record and given to them within 2 to 4 weeks. The other group undergoes delayed genotyping after their participation ends, which is 6 months post-enrollment. This approach allows comparison of outcomes between those who receive early genetic information and those who do not during the study period. During the study, participants clinical outcomes such as ED return visits within 6 months and clinician review of PGx results are monitored. Data collection includes tracking the use of PGx results in care decisions. The total participation time is 6 months, during which patient care and hospital visits are observed to assess the impact of pharmacogenetic testing on emergency care outcomes.

Trial of Precision Medicine in Emergency Departments